Arcadia Biosciences, Inc.
RKDA
$2.88
-$0.0767-2.60%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 15.42% | 6.65% | -4.27% | -14.79% | -37.93% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.42% | 6.65% | -4.27% | -14.79% | -37.93% |
| Cost of Revenue | 36.26% | -3.64% | -25.81% | -30.77% | -61.31% |
| Gross Profit | -9.73% | 23.79% | 46.93% | 19.44% | 129.23% |
| SG&A Expenses | 10.95% | -15.73% | -32.42% | -40.26% | -35.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.99% | -12.90% | -30.75% | -38.01% | -43.00% |
| Operating Income | -16.33% | 21.92% | 41.00% | 47.68% | 45.65% |
| Income Before Tax | 18.89% | 77.67% | 85.59% | 97.72% | 34.06% |
| Income Tax Expenses | 0.00% | -50.00% | -53.33% | -42.86% | -42.86% |
| Earnings from Continuing Operations | 18.87% | 77.63% | 85.55% | 97.67% | 34.07% |
| Earnings from Discontinued Operations | 81.80% | 35.29% | -20.28% | -247.55% | -294.19% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -100.00% | -100.00% | -95.61% | -97.88% |
| Net Income | 49.66% | 62.09% | 56.73% | 65.37% | 9.07% |
| EBIT | -16.33% | 21.92% | 41.00% | 47.68% | 45.65% |
| EBITDA | -19.32% | 20.95% | 41.40% | 48.19% | 45.85% |
| EPS Basic | 63.75% | 76.80% | 76.51% | 81.99% | 44.96% |
| Normalized Basic EPS | 21.40% | 61.01% | 72.55% | 99.84% | 50.64% |
| EPS Diluted | 63.75% | 76.80% | 76.51% | 81.99% | 44.96% |
| Normalized Diluted EPS | 21.40% | 61.01% | 72.55% | 99.84% | 50.64% |
| Average Basic Shares Outstanding | 10.30% | 28.05% | 55.13% | 101.02% | 106.24% |
| Average Diluted Shares Outstanding | 10.30% | 28.05% | 55.13% | 101.02% | 106.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |